Expert Analysis

2008 Update on the Use of Approved HCV Agents

Source: CCO Official Conference Coverage of the 2008 AASLD Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

2008 Update on the Use of Approved HCV Agents

Faculty:

Gregory T. Everson, MD, FACP
Carroll Leevy, MD
K. Rajender Reddy, MD

CREDIT INFORMATION

Release Date: 01/07/09

Expiration Date: 01/06/10

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize new data on the efficacy and safety of approved antiviral agents for the treatment of chronic hepatitis C
Discuss recent findings on the role of adjuvant therapy to improve the efficacy and safety of approved anti-HCV agents
Describe the latest insights into factors associated with sustained virologic response to therapy for chronic hepatitis C

Topics covered include:

Insulin Resistance and HCV Therapy Response
Insulin Resistance, Fibrosis, and Steatosis
Impact of Cytopenia Growth Factor Support on HCV Treatment
SVR Rates in HCV Genotype 1 Patients With Advanced Fibrosis
SVR Rates in HCV Genotype 2/3 Patients With Advanced Fibrosis
Extending Treatment in Genotype 1 Slow Responders
Impact of Baseline Factors and Ribavirin Exposure on Risk of Relapse
High-Dose Peginterferon Alfa-2b Induction Therapy
Early Null Response and Association With SVR

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.